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Abstract
Purpose Nucleolar protein 10 (NOP10) is required for ribosome biogenesis and telomere maintenance and plays a key role 
in carcinogenesis. This study aims to evaluate the clinical and prognostic significance of NOP10 in breast cancer (BC).
Methods NOP10 expression was assessed at mRNA level employing the Molecular Taxonomy of Breast Cancer Interna-
tional Consortium (METABRIC) (n = 1980) and Cancer Genome Atlas (TCGA) BC cohorts (n = 854). Protein expression 
was evaluated on tissue microarray of a large BC cohort (n = 1081) using immunohistochemistry. The correlation between 
NOP10 expression, clinicopathological parameters and patient outcome was assessed.
Results NOP10 expression was detected in the nucleus and nucleolus of the tumour cells. At the transcriptomic and proteomic 
levels, NOP10 was significantly associated with aggressive BC features including high tumour grade, high nucleolar score 
and poor Nottingham Prognostic Index. High NOP10 protein expression was an independent predictor of poor outcome in 
the whole cohort and in triple-negative BC (TNBC) class (p = 0.002 & p = 0.014, respectively). In chemotherapy- treated 
patients, high NOP10 protein expression was significantly associated with shorter survival (p = 0.03) and was predictive of 
higher risk of death (p = 0.028) and development of distant metastasis (p = 0.02) independent of tumour size, nodal stage 
and tumour grade.
Conclusion High NOP10 expression is a poor prognostic biomarker in BC and its expression can help in predicting chemo-
therapy resistance. Functional assessments are necessary to decipher the underlying mechanisms and to reveal its potential 
therapeutic values in various BC subtypes especially in the aggressive TNBC class.
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Introduction
Invasive breast cancer (BC) is a heterogeneous disease with 
a spectrum of different molecular and morphological sub-
types that are variable in behaviour and response to therapy 
[1]. Morphological features such as histological grade have 
a prognostic value and their assessment help in treatment 
decisions of BC patients [2]. Nucleolar aberration either in 
size, shape, or number [3], has been associated with poor 
outcomes in BC [4]. Alterations in the nucleolus during 
tumourigenesis usually take place as a consequence of ele-
vating ribosomal biogenesis to subtend the high demand for 
proteins in cancer cells which is highly required for their 
proliferation [5, 6]. RNA modifications occur in the nucleo-
lus and require hundreds of small nucleolar RNAs (snoR-
NAs), as well as multi-component protein complexes which 
are collectively known as small nucleolar ribonucleoprotein 
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(snoRNP) complexes [7]. Dysregulation of snoRNPs can 
influence the development and progression of various human 
diseases such as Prader Willi syndrome, some metabolic 
stress disorders, and several types of cancer [8–11].
These complexes include two classes, C/D box snoRNPs 
and H/ACA box snoRNPs, which enhance fundamental 
processes in ribosomal RNA modification [12–14]. H/ACA 
RNPs are composed of four main conserved proteins, includ-
ing Nucleolar Protein Family A, Member 3 (NOP10), DKC1 
(Dyskerin), Nucleolar Protein Family A, Member 2 (NHP2) 
and Nucleolar Protein Family A, Member 1 (GAR1) [12]. 
DKC1 expression is upregulated in a number of human can-
cers including BC and its high levels are associated with 
poor prognosis through the disruption of several cellular pro-
cesses including telomere maintenance, mitosis, transcrip-
tion, and RNA processing [15–17]. However, it is unclear 
whether the underlying mechanisms are related only to 
DKC1 dysregulation or perhaps result from a disrupted func-
tion of other proteins in the H/ACA RNPs box. NOP10, also 
known as NOLA3, plays critical roles in diverse processes, 
including the processing of ribosomal RNAs, modification 
of spliceosome small nuclear RNAs, and stabilization of tel-
omerase [18]. It forms a core trimer with DKC1 and NHP2 
where they closely interact with each other and are involved 
in the metabolic stability of RNAs [19, 20].
The current study aims to examine the molecular and 
prognostic value of NOP10 at genomic, transcriptomic, and 
proteomic levels in BC by assessing its association with 
clinicopathological parameters and patient outcome using 
several large cohorts and datasets with the emphasis on the 
different BC molecular subtypes.
Materials and methods
Study cohorts
When the members in H/ACA RNPs box were analysed at 
the transcriptomic levels in both the Molecular Taxonomy 
of Breast Cancer International Consortium (METABRIC) 
cohort (n = 1980) and The Cancer Genome Atlas (TCGA) 
BC dataset (n = 854), NOP10 was highly associated with 
aggressive tumour features and worse patient outcome, 
compared to others. Therefore, NOP10 was selected for this 
study. The METABRIC cohort (n = 1980) was used to evalu-
ate NOP10 gene copy number (CN) aberrations and mRNA 
expression [21]. The TCGA BC dataset and the Breast 
Cancer Gene Expression Miner online dataset v4.3 (https ://
bcgen ex.ico.unica ncer.fr) were used as external validation 
resources of NOP10 mRNA expression [22].
NOP10 protein expression was evaluated on well-char-
acterized large series (n = 1081) of BC patients (Notting-
ham Series) as previously described [23]. Briefly, patients 
were presented at Nottingham City Hospital between 1999 
and 2006. Clinical information and tumour characteristics 
including patient’s age at diagnosis, histological tumour 
type, grade, tumour size, lymph node status, Nottingham 
Prognostic Index (NPI), and lymphovascular invasion (LVI), 
were available. Moreover, the data of the nucleolar scor-
ing of Nottingham and TCGA breast cancer datasets were 
available as previously published [4]. Outcome data were 
obtained and these included BC specific survival (BCSS), 
defined as time (in months) from the date of primary surgical 
treatment to the time of death by BC, and distant metasta-
sis-free survival (DMFS) defined as the time (in months) 
from the surgery until the first event of distant metastasis. 
Post-operative treatment was offered according to the insti-
tutional protocols. Data related to the expression of basic 
BC markers were also available, including oestrogen recep-
tor (ER), progesterone receptor (PR), and human epidermal 
growth factor 2 (HER2) [24–26]. In addition, DKC1 protein 
expression level was assessed on the same cohort. Endocrine 
therapy was given to patients who had ER-positive (ER +) 
tumours with high NPI scores (> 3.4), while no adjuvant 
therapy was given to patients with ‘good’ NPI scores (≤ 3.4). 
Post-menopausal patients with ‘moderate’ or ‘poor’ NPI 
scores were given hormonal therapy, while premenopausal 
patients with moderate and poor NPI scores were subject 
to chemotherapy. Classical treatment of cyclophosphamide, 
methotrexate, and fluorouracil (CMF) was used as a therapy 
for patients presented with the absence of ER expression and 
clinically fit to receive chemotherapy. None of the patients 
in the current study cohort received neoadjuvant therapy. 
The clinicopathological parameters for the METABRIC 
and Nottingham series are summarized in (Supplementary 
Table S1).
NOP10 protein expression evaluation
Prior to immunohistochemistry (IHC) staining of the tis-
sue sections, the specificity of the anti-NOP10 antibody 
(EPR8857, Abcam, UK) was validated by Western blotting 
using cell lysates of HELA, MCF7 and SKBR3 human cell 
lines obtained from American Type Culture Collection, 
Rockville, MD, USA. The NOP10 primary antibody was 
used at 1:1000 dilution. Proteins were detected using IRDye 
800CW fluorescent secondary antibodies (1:15 000 dilu-
tion, LI-COR Biosciences) and the Odyssey Fc with Image 
Studio 4.0 (LI-COR Biosciences) was used to visualize the 
bands. Anti-β-actin primary antibody (Sigma-Aldrich) was 
used as a loading control (1: 5000). A single specific band 
for NOP10 protein was observed at the predicted molecular 
weight (10 kDa) confirming the specificity of the antibody 
(Fig. 1a).
Tumour samples were previously arrayed (TMAs) using 
the Grand Master® (3D HISTECH®, Budapest, Hungary) 
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as described previously [27]. IHC staining was performed on 
4 μm thick sections using the Novocastra Novolink™ Poly-
mer Detection Systems kit (Code: RE7280-K, Leica, Bio-
systems, Newcastle, UK). Antigen retrieval was performed 
in citrate buffer pH 6.0 using a microwave (Whirlpool JT359 
Jet Chef 1000 W) for 20 min. Rabbit monoclonal NOP10 
was diluted at 1:250 in Leica antibody diluent (RE AR9352, 
Leica, Biosystems, UK) and incubated for 60 min at room 
temperature. A negative control was obtained by omitting 
the primary antibody, while normal renal tissue was used as 
a positive control according to the manufacturer’s datasheet.
Scoring NOP10 protein expression
Scoring of NOP10 expression was performed using high-
resolution digital images of the stained TMAs, which were 
obtained via a NanoZoomer scanner (NanoZoomer; Hama-
matsu Photonics, Welwyn Garden City, UK) at 20 × magnifi-
cation and were viewed using Xplore software (Philips, UK). 
Immunoreactivity staining of the nucleus and prominent nucle-
olus [4] were evaluated based on a semi-quantitative scoring 
using a modified histochemical score (H-score), which esti-
mated both the intensity and the percentage of stained tumour 
cells. A score index of 0, 1, 2, and 3 corresponding to a nega-
tive, weak, moderate, and strong staining, respectively, was 
used for intensity scoring. The percentage (0–100) of positive 
cells for each intensity was evaluated. The final H-score was 
calculated by multiplying the percentage of positively stained 
cells in the tissue by the level of intensity, generating a score 
ranging between 0 and 300 [28]. All non-representative cores 
including folded tissue during processing and staining, cores 
with < 15% of invasive tumour tissue were excluded. Scor-
ing was performed by one observer (K. Elsharawy) blinded of 
clinicopathological and patients’ outcome data. Moreover, the 
inter-observer’s reproducibility of the scoring was considered. 
A subset of cores (10%) was randomly selected and double 
scored blindly by another observer (M. Althobiti).
This work obtained ethics approval to use the human tis-
sue samples by the North West – Greater Manchester Central 
Research Ethics Committee under the title; Nottingham Health 
Science Biobank (NHSB), reference number 15/NW/0685. 
Informed consent was obtained from all individuals prior to 
surgery to use their tissue materials in research.
Statistical analysis
NOP10 expression for proteomic and transcriptomic was cat-
egorized using X-tile bioinformatics software version 3.6.1 
(School of Medicine, Yale University, New Haven, USA) 
based on a prediction of BCSS [29]. IBM-SPSS statistical 
software 24.0 (SPSS, Chicago, IL, USA) was used for statisti-
cal analysis. Inter-observer agreement in NOP10 IHC scoring 
was assessed using intra-class correlation coefficient (ICC). 
The Chi-square test was performed for correlations between 
categorical variables. Spearman’s rank correlation coefficient 
was carried out to examine the association between NOP10 
and other related markers. Univariate survival analysis was 
carried out using Kaplan–Meier curves and log rank test. 
Cox’s regression models were used for the multivariate sur-
vival analysis to adjust for confounding factors. For all tests, 
p-value < 0.05 was considered statistically significant.
This study followed the reporting recommendations for 
tumour markers prognostic studies (REMARK) criteria [30] 
(Supplementary Table S2).
Results
Genomic and transcriptomic expression of NOP10
High NOP10 mRNA expression (log2 intensity > 11.2) was 
observed in 493/1968 (25%) of the METABRIC cases. A 
Fig. 1  a Western blotting of anti-NOP10 antibody in HELA, MCF7 
and SKBR3 cell lysates showing a single specific band (lower green 
band) at expected molecular weight (10KDa). The upper red band 
represented β-actin (positive control) at 42 kDa, b Negative NOP10 
IHC expression, c Positive NOP10 IHC nuclear expression and d 
Positive NOP10 IHC nucleolar expression in invasive breast cancer 
TMA cores
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significant association was observed between high NOP10 
mRNA expression and NOP10 gene copy number (CN) gain 
(p < 0.0001). High NOP10 mRNA expression was signifi-
cantly associated with features characteristic of poor prog-
nosis including younger age, higher tumour grade, poorer 
NPI scores, hormone receptor negativity, HER2 positivity, 
TNBC phenotype (all p < 0.0001) and advance nodal stage 
(p = 0.001). According to the intrinsic PAM50 subtypes [31], 
higher expression of NOP10 mRNA was found mainly in 
basal-like BC (p < 0.0001) (Table 1).
TCGA BC dataset showed similar significant results 
in addition to the association with nucleolar score 3 
(p < 0.0001) [4] (Table 1). The association between NOP10 
mRNA and aggressive features of the tumour were also dem-
onstrated and confirmed in the Breast Cancer Gene Expres-
sion Miner v4.3 database (Supplementary Fig. S1a-h).
NOP10 protein expression
NOP10 protein expression was observed mainly in the 
nucleus and nucleolus of invasive tumour cells, with expres-
sion levels varying from negative to strong (Fig. 1b, c and 
d). Excellent concordance was observed between the two 
observers (ICC = 0.803, p < 0.0001 for nuclear expression 
& ICC = 0.721, p < 0.0001 for nucleolar expression). High 
NOP10 nuclear and nucleolar expression (cut-off > 120 
H-score & > 0 H-score, respectively) were displayed in 
847/1081 (78%) and 58/1081 (5%) of BC cases.
High expression of NOP10 protein whether in the nucleus 
or in the nucleoli showed a significant association with 
aggressive characteristics including; higher tumour grade 
(p < 0.0001), poor NPI (p = 0.006 & p = 0.002), higher 
mitotic scores (p = 0.0003 & p = 0.0002), higher nuclear 
pleomorphism (p < 0.0001 & p = 0.017) and higher nucleo-
lar score (p = 0.003 & p < 0.0001). High NOP10 nucleolar 
protein expression was significantly associated with receptor 
negativity (ER-, PR- and TNBC phenotype) (all p < 0.0001) 
(Table 2).
NOP10 and other related biomarkers
The correlation of NOP10 mRNA with other genes in H/
ACA snoRNPs was investigated using the METABRIC 
and TCGA datasets. NOP10 was positively associated 
with DKC1 (correlation coefficient (r) = 0.082 & 0.151, 
p = 0.0002 & p < 0.0001), GAR1 (r = 0.264 & 0.413, both 
p < 0.0001), and NHP2 (r = 0.214 & 0.447, both p < 0.0001) 
in METABRIC and TCGA, respectively. Moreover, there 
was a significant association with the regulatory gene MYC 
(r = 0.313 & 0.092, p < 0.0001 & p = 0.007) (correlation 
matrix of NOP10 with other related genes in snoRNPs 
is shown in Supplementary Fig. S2a & b). High NOP10 
mRNA expression was associated with tumours exhibiting 
TP53 mutations (p = 0.009, Table 1) in the METABRIC 
cohort.
At the protein level, there was a significant positive cor-
relation between NOP10 and DKC1 nuclear expression 
(r = 0.284, p < 0.0001).
NOP10 and patients’ outcome
In the METABRIC cohort, high NOP10 mRNA expression 
was associated with poor outcome in terms of shorter BCSS 
(HR = 1.3, 95%CI = 1.0–1.5; p = 0.023). When the cohort 
was stratified according to the molecular subtypes, high 
NOP10 mRNA expression was predictive of shorter BCSS 
in HER2 enriched tumours (HR = 1.6, 95%CI = 1.1–2.5; 
p = 0.016) but not in other classes (Fig. 2a–e). Similarly, 
in the TCGA cohort, there was an association between 
high NOP10 mRNA expression and poor patient out-
come in all cases and in the HER2 + tumours (HR = 1.8, 
95%CI = 1.1–3.1; p = 0.035 & HR = 3.7, 95%CI = 1.2–11.5; 
p = 0.022), (Supplementary Fig. S3a–d).
At the protein level, high NOP10 nuclear protein expres-
sion was significantly associated with shorter BCSS 
(HR = 1.9, 95%CI = 1.3–3.1; p = 0.001) and shorter DMFS 
(HR = 1.8, 95%CI = 1.3–2.7; p = 0.001) in the whole cohort, 
and in the TNBC class (HR = 4.9, 95%CI = 1.2–20.5; 
p = 0.014 and HR = 5.3, 95%CI = 1.3–21.8; p = 0.01) for 
BCSS and DMFS, respectively) (Fig. 3a–g and Supplemen-
tary Fig. S4a-e).
Combinatorial NOP10 protein expression groups [low 
nuclear/low nucleolar, high nuclear/low nucleolar, low 
nuclear/high nucleolar and high nuclear/high nucleolar 
expression] showed a significant difference in BCSS among 
these groups with the high nuclear/high nucleolar NOP10 
expression group showing the worst outcome (p = 0.011) 
(Fig. 3c).
In multivariate Cox regression models including other 
prognostic covariates (tumour size, grade and nodal stage), 
NOP10 mRNA was an independent predictor of shorter 
BCSS (p = 0.04, HR 1.3, 95% CI = 1.0–1.7) (Supplementary 
Table S3). High NOP10 nuclear and combinatorial protein 
expression (high nuclear/high nucleolar) were independ-
ent predictors of poor prognosis in all cases (p = 0.002, HR 
1.9, 95% CI = 1.3 –2.9 & p = 0.005, HR 1.3, 95% CI = 1.1 
– 1.6) and in TNBC cases only (p = 0.014, HR 5.9, 95% 
CI = 1.4–24.9 & p = 0.04, HR 1.6, 95% CI = 1.1–2.6) as 
shown in Table 3.
When patients were classified based on therapy, high 
NOP10 protein expression in patients who received chemo-
therapy was significantly associated with shorter BCSS 
(HR = 1.6, 95%CI = 1.0–2.5; p = 0.039) and higher risk 
of early distant metastasis (HR = 1.6, 95%CI = 1.0–2.4; 
p = 0.035). However, such association was not observed 
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Table 1  Association of NOP10 mRNA expression with clinicopathological parameters in the Molecular Taxonomy of Breast Cancer Interna-
tional Consortium (METABRIC) and in the Cancer Genome Atlas (TCGA) breast cancer series
P values in bold means statistically significant, N/A not available
Parameters METABRIC TCGA 
NOP10 mRNA Chi- square (χ2) 
(p-value)
NOP10 mRNA Chi- square 
(χ2) 
(p-value)Low N (%) High N (%) Low N (%) High N (%)
Patient age
  ≤ 50 245 (65) 135 (35) 28.5
 < 0.0001
180 (83) 36 (17) 6.5
0.011  > 50 1202 (78) 345 (22) 525 (90) 59 (10)
Tumour size
  ≤ 2 cm 442 (71) 178 (29) 6.4
0.012
206 (93) 16 (7) 6.4
0.011  > 2 cm 1012 (77) 309 (23) 499 (86) 79 (14)
Axillary node stage
 Negative 1247 (76) 401 (24) 14.9
0.001
355 (89) 44 (11) 0.5
0.5 Positive 224 (72) 89 (28) 347 (87) 50 (13)
Lympho-vascular Invasion
 Negative N/A N/A N/A 474 (90) 52 (10) 5.8
(0.016) Positive 231 (84) 43 (16)
PAM50 subtypes
 Luminal A 620 (86) 97 (14) 102.1
 < 0.0001
N/A N/A N/A
 Luminal B 335 (69) 151 (31)
 Basal like 206 (63) 120 (37)
 HER2 151 (64) 85 (36)
 Normal 158 (80) 39 (20)
Nottingham prognostic index (NPI)
 Good 548 (81) 129 (19) 25.5
<0.0001
N/A N/A N/A
 Moderate 799 (73) 295 (27)
 Poor 128 (65) 69 (35)
Tumour grade
 Grade 1 137 (81) 32 (19) 35.4
 < 0.0001
80 (96) 3 (4) 25.7
 < 0.0001 Grade 2 619 (81) 149 (19) 324 (93) 26 (7)
 Grade 3 649 (69) 295 (31) 270 (82) 61 (18)
Nucleolar score
 Score 1 N/A N/A N/A 269 (94) 17(6) 48.2
 < 0.0001 Score 2 204 (88) 27 (12)
 Score 3 42 (64) 24 (36)
Oestrogen receptor
 Negative 287 (62) 180 (38) 59.4
 < 0.0001
127 (73) 47 (27) 49.2
 < 0.0001 Positive 1188 (79) 313 (21) 549 (92) 47 (8)
Progesterone receptor
 Negative 63 (69) 293 (31) 39.1
 < 0.0001
199 (78) 57 (22) 39.5
 < 0.0001 Positive 838 (81) 200 (19) 471 (93) 37(7)
Human epidermal growth factor receptor 2 (HER2) status
 Negative 1329 (77) 399 (23) 29.1
 < 0.0001
487 (90) 54 (10) 8.2
0.017 Positive 146 (61) 94 (39) 102 (81) 24 (19)
Triple-negative status
 Non-triple negative 1270 (77) 381 (23) 21.3
<0.0001
N/A N/A N/A
 Triple negative 205 (65) 112(35)
TP53 mutations
 Wild type 531 (74) 188 (26) 6.9
0.009
N/A N/A N/A
 Mutation 58 (61) 37 (39)
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in those who did not receive systemic chemotherapy 
(Fig. 4a-d).
In the chemotherapy-treated cohort, high NOP10 nuclear 
expression was predictive of a higher risk of death from 
breast cancer (p = 0.028, HR 1.6, 95% CI = 1.1–2.6) and 
development of distant metastasis (p = 0.02, HR 1.6, 95% 
CI = 1.1–2.5), independent of tumour size, nodal stage and 
tumour grade (Table 4).
Discussion
Ribosome production is an essential process during neoplas-
tic transformation. Regulation of cellular growth and prolif-
eration mainly depends on the rate of ribosomal biogenesis. 
Cancer cells required increased production of ribosomes 
to sustain their high demand for protein synthesis. Protein 
synthesis requires ribosomal RNAs besides the protein com-
ponents of the translation machinery [6].
The underlying molecular mechanisms of ribosomal 
modifications in various human diseases including malig-
nancy are diverse and not fully understood [32–34]. Previous 
studies on neuroblastoma and lymphocytic leukemia dem-
onstrated that snoRNP signature displayed highly significant 
prognostic value and was an independent predictor of poor 
prognosis through its effect on genomic stability and tel-
omere maintenance [10, 11].
NOP10 is one of four essential protein components of H/
ACA snoRNPs, which plays a potential role in facilitating 
the modification and stabilization of ribosomal RNAs. In 
addition, NOP10 is required for optimal enzymatic activity 
[35].
To further explore the potential value of snoRNPs family, 
we investigated for the first time, to the best our knowledge, 
the prognostic and predictive significance of NOP10 in BC 
using genomic, transcriptomic, and proteomic data of large 
BC cohorts. NOP10 protein expression was assessed in the 
nuclei and nucleoli of BC cells to determine its association 
with the nucleolar score [4].
The number and size of nucleoli as a consequence of its 
elevated activity in ribosomal biogenesis has been widely 
used as a prognostic marker of aggressive cancer [4, 36]. 
In the current study, a significant association between high 
NOP10 at both level protein (whether in nucleus or nucleoli) 
and mRNA expression (transcriptomic) with the nucleolar 
score (phenotype) was observed. These findings may sup-
port the speculation that NOP10 expression correlates with 
nucleoli appearance and size through its functional role in 
ribosomal RNA modification.
We revealed the significant association between the 
high expression of NOP10, at both protein and mRNA 
levels, and poor prognostic clinicopathological param-
eters and worse survival supporting its importance in BC 
progression. These data are in accordance with a study 
which showed alterations in NOP10 mRNA are associated 
with poor prognosis in endometrial cancer [37]. Moreover, 
we demonstrated a significant association between NOP10 
mRNA expression and CN variation which supports the 
idea that hypotheses the diverging expression of snoRNPs 
could be closely associated with an overall elevation in 
genetic aberrations in BC [10, 38]. We reported a higher 
percentage in NOP10 expression at the proteomic level 
compared to the mRNA level, this could be related to sam-
ple fixation, age of stored samples or the specificity of 
antigen retrieval technique [39, 40]. Also, transcriptomic 
data reflects the mRNA level of all cells within the tissue 
samples either tumour cells or other surrounding cells.
We also evaluated the association of NOP10 and BC 
subtypes. NOP10 protein expression was significantly 
associated with shorter DMFS and BCSS in TNBC, while 
mRNA predicted poor outcome in HER2+ tumours. Such 
discrepancies might be attributed to the differences in the 
number of cases in each subtype between the Nottingham 
and METABRIC cohorts or might be due to tumour-spe-
cific differences in NOP10 mRNA/protein stability or post-
transcriptional regulation of NOP10 expression.
NOP10 protein expression was independent prognostic 
markers in all cases and in TNBC, which may have poten-
tial clinical relevance in improving survival rate predic-
tion. TNBC is highly malignant, prone to metastasis and 
relapse, and significantly correlated with a poorer progno-
sis and a greater risk of mortality comparing to other BC 
subtypes [41, 42]. NOP10 elevation is doubtlessly attribut-
able to TNBC aggressive character through its heavier pro-
tein requirements for cell survival and proliferation which 
is compatible with increased rRNA synthesis [43]. This 
implies that NOP10 plays a role in tumourigenic pathways 
and could be a marker of poor prognosis in TNBC.
Since high expression of NOP10 was associated with 
worse prognostic features and outcome in patients with 
TNBC subtype, we hypothesized that NOP10 may play an 
important role in response to chemotherapy. Our findings 
showed that patients with high NOP10 expression showed 
poorer outcome than those with low levels of NOP10 
even when chemotherapy was received which indicates 
that NOP10 could potentially contribute to chemotherapy 
resistance. These findings suggest that assessment of 
NOP10 expression prior to adjuvant treatment could pre-
dict the chemotherapy resistance and eventually tumour 
relapse.
NOP10 plays a critical role for the stability of the 
domain as well as in the assembly and integrity of H/ACA 
snoRNPs complexes (DKC1, NHP2, NOP10 & GAR1), 
where they implicated mainly in the isomerization of uri-
dine to pseudouridine thereby, promote the folding and 
stabilization of RNAs, such as the local RNA structure in 
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Table 2  Clinicopathological associations of NOP10 nuclear & nucleolar protein expression in Nottingham cohort
Parameter NOP10 nuclear expression Chi- square (χ2) 
(p-value)
NOP10 nucleolar expression Chi- square 
(χ2) 
(p-value)Low N (%) High N (%) Low N (%) High N (%)
Patient age
  ≤ 50 years 83 (21) 317 (79) 0.32
0.58
342 (94) 22 (6) 0.49
0.48  > 50 years 151 (22) 529 (78) 681 (95) 36 (5)
Tumour size
  ≤ 2 cm 143 (21) 523 (79) 0.02
0.9
609 (95) 29 (5) 2.11
0.14  > 2 cm 90 (22) 323 (78) 412 (93) 29 (7)
Axillary nodal stage
 Stage 1 138 (21) 521 (79) 0.82
0.66
619 (94) 40 (6) 1.60
0.44 Stage 2 72 (23) 236 (77) 295 (96) 13 (4)
 Stage 3 23 (21) 89 (79) 107 (95) 5 (5)
Lympho-vascular invasion
 Negative 157 (21) 598 (79) 0.95
0.33
711 (94) 44 (6) 1.10
0.31 Positive 76 (24) 248 (76) 310 (96) 14 (4)
Histological subtypes
 Lobular 26 (35) 48 (65) 22.10
0.0002
74 (100) 0 (0) 19.80
0.001 Tubular 35 (32) 76 (68) 53 (96) 2 (4)
 Non-specific type(NST) 140 (18) 633 (82) 134 (100) 0 (0)
 Mixed NST and lobular 15 (28) 39 (72) 760 (96) 32 (4)
 Other special type* 18 (26) 51 (74) 62 (89) 8 (11)
Nottingham prognostic index (NPI)
 Good 42 (22) 152 (78) 10.40
0.006
188 (96) 8 (4) 12.40
0.002 Moderate 111 (28) 486 (72) 573 (95) 32 (5)
 Poor 79 (19) 201 (81) 312 (99) 2 (1)
Tumour grade
 Grade 1 36 (53) 32 (47) 44.90
 < 0.0001
68 (100) 0 (0) 19.40
 < 0.0001 Grade 2 95 (22) 339 (78) 423 (97) 11 (3)
 Grade 3 102 (18) 476 (82) 531 (92) 47 (8)
Nuclear pleomorphism
 Score 1 4 (67) 2 (33) 18.7
 < 0.0001
6 (100) 0 (0) 8.2
0.017 Score 2 67 (29) 162 (71) 225 (98) 4 (2)
 Score 3 158 (19) 676 (81) 780 (93) 54 (7)
Mitosis
 Score 1 114 (27) 306 (73) 16.7
0.0003
412 (98) 8 (2) 17.4
0.0002 Score 2 51 (22) 184 (78) 219 (93) 16 (7)
 Score 3 64 (15) 348 (85) 378 (92) 34 (8)
Tubule formation
 Score 1 16 (47) 18 (53) 13.9
0.001
34 (100) 0 (0) 6.1
0.047 Score 2 60 (22) 217 (78) 268 (97) 9 (3)
 Score 3 153 (20) 605 (80) 709 (93) 49 (7)
Nucleolar score
 Score 1 88 (27) 234 (73) 11.9
0.003
341 (99) 2 (1) 98.2
 < 0.0001 Score 2 78 (19) 331 (81) 416 (99) 3 (1)
 Score 3 32 (16) 171 (84) 173 (84) 32 (16)
Oestrogen receptor
 Negative 45 (19) 193 (81) 1.4
0.25
207 (87) 31 (13) 35.3
 < 0.0001 Positive 189 (22) 654 (78) 816 (97) 27 (3)
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the ribosome [44]. The current study confirmed the cor-
relation among the gene expressions of all H/ACA ribo-
nucleoproteins. High NOP10 protein expression was cor-
related with the high level of DKC1, indicating a system 
of functional coupling between these biomarkers at the 
protein level in isomerization and stabilization of RNAs.
Biogenesis of H/ACA snoRNPs is regulated in response 
to high demands for protein synthesis and c-Myc plays a 
crucial role in regulating cellular growth, size, and pro-
tein synthesis. Our study revealed a positive significant 
relationship between NOP10 and c-Myc. Therefore, it can 
be speculated that modulation of c-Myc transcriptional 
activity may regulate NOP10 expression in order to ful-
fil increased demands for protein synthesis that is highly 
required to maintain the proliferation and self-renewal of 
tumour cells [45–47].
TP53 mutations were also highly prevalent in breast 
tumours where there was high NOP10 mRNA expression. 
Marcel et al. have demonstrated that the level of rRNA meth-
ylation usually increased in cancer cells with dysfunctional 
p53, substantially elucidating that rRNA modifications con-
tribute to the tumourigenic process. The high level of rRNA 
methylation resulted in initiating protein translation through 
a process called internal ribosome entry sequences (IRESs) 
Table 2  (continued)
Parameter NOP10 nuclear expression Chi- square (χ2) 
(p-value)
NOP10 nucleolar expression Chi- square 
(χ2) 
(p-value)Low N (%) High N (%) Low N (%) High N (%)
Progesterone receptor
 Negative 101 (21) 374(79) 0.04
0.84
433 (91) 42 (9) 21.4
 < 0.0001 Positive 131 (22) 471 (78) 587 (97) 15 (3)
Human epidermal growth factor receptor 2 (HER2) status
 Negative 202 (22) 719 (78) 0.3
0.58
874 (95) 47 (5) 0.8
0.4 Positive 32 (20) 128 (80) 149 (93) 11 (7)
Triple negative status
 Non-triple negative 199 (22) 702 (78) 0.6
0.432
867 (96) 34 (4) 27.1
 < 0.0001 Triple negative 35 (19) 145 (81) 156 (87) 24 (13)
* Other special types include tubular, mucinous, cribriform, papillary, micropapillary
P values in bold means statistically significant
Fig. 2  NOP10 mRNA expression and breast-cancer-specific survival (BCSS) in a All cases, b oestrogen receptor (ER)-positive tumours and c 
ER-negative tumours. d Human epidermal growth factor receptor 2 (HER2 +) tumours. e Triple-negative tumours in the METABRIC cohort
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which resulted in products that promote tumour development 
(The insulin-like growth factor 1 (IGF-1R), c-Myc, Vascular 
endothelial growth factor A (VEGF-A) and acidic fibroblast 
growth factor (FGF1)) [47–49].
Despite the remarkable results this study presents, there 
are some identified limitations. The subjectivity of the semi-
quantitative H-score method, that has been used to score the 
sections, is one of our study weaknesses. It was aimed to 
reduce the impact of this limitation by allowing two well-
trained observers to score about 10% of the cores to ensure 
the reproducibility and liability of the procedure. On the 
other hand, using TMA could underestimate the role of 
tumour heterogeneity.
Fig. 3  NOP10 protein expression and breast-cancer-specific survival 
(BCSS). a NOP10 nuclear expression and BCSS. b NOP10 nucleo-
lar expression and BCSS. c combinatorial NOP10 protein expres-
sion and BCSS. d NOP10 and BCSS in oestrogen receptor (ER)-
positive tumours. e NOP10 and BCSS in (ER)-negative tumours. f 
NOP10 and BCSS human epidermal growth factor receptor 2-positive 
(HER2 +) tumours. g NOP10 and BCSS of triple-negative tumours in 
Nottingham cohort
Table 3  Multivariate Cox regression analysis results for predictors of Breast-Cancer-Specific Survival in Nottingham cohort
P values in bold means statistically significant














Lower Upper Lower Upper
(A) NOP10 nuclear expression 1.9 1.3 2.9 0.002 5.9 1.4 24.9 0.014
Tumour size 1.6 1.2 2.2 0.002 1.3 0.7 2.4 0.465
Tumour stage 1.8 1.5 2.2 < 0.0001 1.9 1.3 3.2 0.004
Tumour grade 1.9 1.4 2.6 0.00016 0.9 0.4 2.6 0.969
(B) NOP10 nucleolar expression 0.9 0.9 1.0 0.29 0.4 0.05 2.7 0.329
Tumour size 1.5 1.1 1.9 0.004 1.3 0.7 2.4 0.425
Tumour stage 1.9 1.6 2.2 < 0.0001 1.9 1.2 2.8 0.002
Tumour grade 2.0 1.6 2.6 < 0.0001 0.9 0.5 2.1 0.944
(C) NOP10 combinatorial protein expression 1.3 1.1 1.6 0.005 1.6 1.1 2.6 0.04
Tumour size 1.6 1.2 2.2 0.002 1.4 0.7 2.5 0.332
Tumour stage 1.8 1.5 2.2 < 0.0001 1.8 1.2 2.7 0.002
Tumour grade 1.9 1.4 2.6 < 0.0001 0.8 0.4 1.7 0.581
 Breast Cancer Research and Treatment
1 3
In conclusion, our study revealed the prognostic and pre-
dictive importance of NOP10 in BC. NOP10 was associ-
ated with poor prognostic characteristics and poor survival 
outcome. Overexpression of NOP10 appears to play a role 
in the progression of TNBC and is potentially predictive for 
selecting patients who might develop resistance to chemo-
therapy. Thus, it could act as a potential prognostic marker 
and a therapeutic target. Functional assessment is warranted 
to reveal the specific role played by NOP10 in the BC, espe-
cially in the highly proliferative molecular subtypes.
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